{"id":14189,"date":"2024-11-22T17:43:44","date_gmt":"2024-11-22T09:43:44","guid":{"rendered":"https:\/\/flcube.com\/?p=14189"},"modified":"2024-11-22T17:43:47","modified_gmt":"2024-11-22T09:43:47","slug":"pfizer-and-flagship-pioneering-expand-partnership-with-two-new-biotechnology-agreements","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=14189","title":{"rendered":"Pfizer and Flagship Pioneering Expand Partnership with Two New Biotechnology Agreements"},"content":{"rendered":"\n

The billion-dollar, multi-program partnership between US pharmaceutical giant Pfizer (NYSE: PFE<\/a>) and bioplatform innovation company Flagship Pioneering, initiated in July 2023, has expanded with two new additions. Ampersand Biomedicines and Montai Therapeutics, both Flagship-founded biotechs, have entered into agreements to identify targeted molecules aimed at treating obesity and non-small cell lung cancer (NSCLC). While financial details of these specific agreements were not disclosed, the overarching collaboration involved an initial investment of USD 50 million from each party to develop 10 candidate drugs, with Pfizer holding the rights to purchase.<\/p>\n\n\n\n

Building on Existing Collaborations<\/strong>
Prior to these new agreements, Pfizer had already joined forces with another Flagship-founded company, ProFound Therapeutics, in June of this year to develop potential first-in-class obesity therapeutics. Following this, two months later, Pfizer began collaborating with Quotient Therapeutic, another Flagship offshoot, to analyze somatic mutations occurring in patient tissues. This collaboration aims to discover potential transformative therapies for cardiovascular and kidney diseases.<\/p>\n\n\n\n

Expanding the Scope of Precision Medicine<\/strong>
These collaborations underscore Pfizer’s commitment to expanding the scope of precision medicine and targeted therapies. By partnering with Flagship-founded biotechs, Pfizer is leveraging innovative platforms to identify and develop new treatments for a range of diseases, from obesity to non-small cell lung cancer and beyond.-Fineline Info & Tech<\/a><\/p>\n\n\n\n

<\/p>\n","protected":false},"excerpt":{"rendered":"

The billion-dollar, multi-program partnership between US pharmaceutical giant Pfizer (NYSE: PFE) and bioplatform innovation company…<\/p>\n","protected":false},"author":1,"featured_media":14192,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":false,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,10],"tags":[2269,16,2270,863,86,309],"class_list":["post-14189","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-deals","tag-ampersand-biomedicines","tag-cancer","tag-montai-therapeutics","tag-nyse-pfe","tag-obesity","tag-pfizer"],"yoast_head":"\nPfizer and Flagship Pioneering Expand Partnership with Two New Biotechnology Agreements - Insight, China's Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"The billion-dollar, multi-program partnership between US pharmaceutical giant Pfizer (NYSE: PFE) and bioplatform innovation company Flagship Pioneering, initiated in July 2023, has expanded with two new additions. Ampersand Biomedicines and Montai Therapeutics, both Flagship-founded biotechs, have entered into agreements to identify targeted molecules aimed at treating obesity and non-small cell lung cancer (NSCLC). While financial details of these specific agreements were not disclosed, the overarching collaboration involved an initial investment of USD 50 million from each party to develop 10 candidate drugs, with Pfizer holding the rights to purchase.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=14189\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Pfizer and Flagship Pioneering Expand Partnership with Two New Biotechnology Agreements\" \/>\n<meta property=\"og:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=14189\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China's Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2024-11-22T09:43:44+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2024-11-22T09:43:47+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/013.png\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"720\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=14189#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=14189\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Pfizer and Flagship Pioneering Expand Partnership with Two New Biotechnology Agreements\",\"datePublished\":\"2024-11-22T09:43:44+00:00\",\"dateModified\":\"2024-11-22T09:43:47+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=14189\"},\"wordCount\":219,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=14189#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/013.png\",\"keywords\":[\"Ampersand Biomedicines\",\"Cancer\",\"Montai Therapeutics\",\"NYSE: PFE\",\"Obesity\",\"Pfizer\"],\"articleSection\":[\"Company\",\"Deals\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=14189#respond\"]}],\"copyrightYear\":\"2024\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=14189\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=14189\",\"name\":\"Pfizer and Flagship Pioneering Expand Partnership with Two New Biotechnology Agreements - Insight, China's Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=14189#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=14189#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/013.png\",\"datePublished\":\"2024-11-22T09:43:44+00:00\",\"dateModified\":\"2024-11-22T09:43:47+00:00\",\"description\":\"The billion-dollar, multi-program partnership between US pharmaceutical giant Pfizer (NYSE: PFE) and bioplatform innovation company Flagship Pioneering, initiated in July 2023, has expanded with two new additions. Ampersand Biomedicines and Montai Therapeutics, both Flagship-founded biotechs, have entered into agreements to identify targeted molecules aimed at treating obesity and non-small cell lung cancer (NSCLC). While financial details of these specific agreements were not disclosed, the overarching collaboration involved an initial investment of USD 50 million from each party to develop 10 candidate drugs, with Pfizer holding the rights to purchase.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=14189#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=14189\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=14189#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/013.png\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/013.png\",\"width\":1080,\"height\":720,\"caption\":\"Pfizer and Flagship Pioneering Expand Partnership with Two New Biotechnology Agreements\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=14189#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Pfizer and Flagship Pioneering Expand Partnership with Two New Biotechnology Agreements\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Pfizer and Flagship Pioneering Expand Partnership with Two New Biotechnology Agreements - Insight, China's Pharmaceutical Industry","description":"The billion-dollar, multi-program partnership between US pharmaceutical giant Pfizer (NYSE: PFE) and bioplatform innovation company Flagship Pioneering, initiated in July 2023, has expanded with two new additions. Ampersand Biomedicines and Montai Therapeutics, both Flagship-founded biotechs, have entered into agreements to identify targeted molecules aimed at treating obesity and non-small cell lung cancer (NSCLC). While financial details of these specific agreements were not disclosed, the overarching collaboration involved an initial investment of USD 50 million from each party to develop 10 candidate drugs, with Pfizer holding the rights to purchase.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=14189","og_locale":"en_US","og_type":"article","og_title":"Pfizer and Flagship Pioneering Expand Partnership with Two New Biotechnology Agreements","og_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","og_url":"https:\/\/flcube.com\/?p=14189","og_site_name":"Insight, China's Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2024-11-22T09:43:44+00:00","article_modified_time":"2024-11-22T09:43:47+00:00","og_image":[{"width":1080,"height":720,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/013.png","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=14189#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=14189"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Pfizer and Flagship Pioneering Expand Partnership with Two New Biotechnology Agreements","datePublished":"2024-11-22T09:43:44+00:00","dateModified":"2024-11-22T09:43:47+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=14189"},"wordCount":219,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=14189#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/013.png","keywords":["Ampersand Biomedicines","Cancer","Montai Therapeutics","NYSE: PFE","Obesity","Pfizer"],"articleSection":["Company","Deals"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=14189#respond"]}],"copyrightYear":"2024","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=14189","url":"https:\/\/flcube.com\/?p=14189","name":"Pfizer and Flagship Pioneering Expand Partnership with Two New Biotechnology Agreements - Insight, China's Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=14189#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=14189#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/013.png","datePublished":"2024-11-22T09:43:44+00:00","dateModified":"2024-11-22T09:43:47+00:00","description":"The billion-dollar, multi-program partnership between US pharmaceutical giant Pfizer (NYSE: PFE) and bioplatform innovation company Flagship Pioneering, initiated in July 2023, has expanded with two new additions. Ampersand Biomedicines and Montai Therapeutics, both Flagship-founded biotechs, have entered into agreements to identify targeted molecules aimed at treating obesity and non-small cell lung cancer (NSCLC). While financial details of these specific agreements were not disclosed, the overarching collaboration involved an initial investment of USD 50 million from each party to develop 10 candidate drugs, with Pfizer holding the rights to purchase.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=14189#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=14189"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=14189#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/013.png","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/013.png","width":1080,"height":720,"caption":"Pfizer and Flagship Pioneering Expand Partnership with Two New Biotechnology Agreements"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=14189#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Pfizer and Flagship Pioneering Expand Partnership with Two New Biotechnology Agreements"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/013.png","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/14189","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=14189"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/14189\/revisions"}],"predecessor-version":[{"id":14193,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/14189\/revisions\/14193"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/14192"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=14189"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=14189"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=14189"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}